Pfizer Settles With Purchasers for $94 Million Over Celebrex Pay-For-Delay Deal

Drug Industry Daily
A A
Pfizer reached a $94 million settlement with a class of direct purchasers over claims it used fraudulent patents to keep generic competition off the market for its anti-inflammatory drug Celebrex.

To View This Article:

Login

Subscribe To Drug Industry Daily